Top-tier capacity Leverage Chartwell’s multi-site cGMP manufacturing and dedicated beta-lactam facility to propose scalable API and finished dosage form manufacture, packaging, and clinical supply services for clients seeking reliable US and Canada-based production.

Expansion readiness Position as a partner for clients needing capacity expansion or technology upgrades, highlighting recent plant expansions, acquisitions, and growth into Beta-Lactam, Unit Dose Liquids, and forthcoming Semi-Solids offerings.

Diverse catalog Emphasize the breadth of nearly 1,200 ANDAs and 750+ commercialized NDCs, with sole-source and dual-source opportunities, to pitch competitive sourcing, portfolio breadth, and regulatory readiness including Trade Act and Buy American Act compliance.

Global regulatory Capitalize on presence of a Beta-Lactam facility in Toronto and strong regulatory track record to target buyers seeking cross-border supply, reliability, and compliance for North American markets.

Strategic partnerships Highlight ongoing investments in new dosage forms and technologies as a selling point to clients needing innovative development, technology transfer, and end-to-end lifecycle support from API characterization to full-scale commercialization.